Lars Fruergaard Jørgensen, CEO of Novo Nordisk, to step down as company seeks a turnaround. Company found success with Wegovy and Ozempic, but share price has fallen by half in past year.

It’s the end of an era at Novo as longtime CEO Lars Fruergaard Jørgensen—who shepherded the company through its GLP-1 growth boom—heads for the exit.

Lars Fruergaard Jorgensen's departure comes a week after the company downgraded its sales and profits forecast, and follows a more than 50% decline in the company's shares since mid-2024.

Lars Fruergaard Jorgensen’s departure comes a week after the company downgraded its sales and profits forecast and follows a more than 50% decline in the company’s shares since mid-2024.

Lars Fruergaard Jorgensen had led Denmark’s Novo since 2017. Ritzau Scanpix/AFP via Getty Images. He told Reuters that discussions to replace Jorgensen had taken place over the past few weeks.

When Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen dialed into a Teams video call with Chairman Helge Lund, he was expecting an ordinary catchup. advertisement.

Lars Rebien Sørensen has pharmaceutical industry expertise from his 16-year tenure as CEO. In the pre-market trading, 5.37% lesser at $62.60 on the New York Stock Exchange.

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to support a smooth transition to new leadership.

Novo Nordisk A/S is replacing Chief Executive Officer Lars Fruergaard Jorgensen as the drugmaker wrestles with increased competition for its Wegovy obesity shots that transformed the weight-loss ...

Bagsværd, Denmark, 16 May 2025 – Novo Nordisk today announced changes to its executive leadership and Board of Directors. As per mutual agreement with the Novo Nordisk Board, Lars Fruergaard ...